Valuation: Abivax

Market Cap 7.07B 7.89B 6.52B 5.9B 11.04B 752B 11.22B 77.82B 31.04B 393B 29.62B 28.99B 1,246B P/E 2026 *
-20.2x
P/E 2027 * -20.2x
Enterprise Value 6.05B 6.76B 5.58B 5.05B 9.45B 644B 9.6B 66.62B 26.58B 337B 25.36B 24.82B 1,067B EV / Sales 2026 *
1,512x
EV / Sales 2027 * 84.2x
Free-Float
92.2%
Yield 2026 *
-
Yield 2027 * -
1 day+0.43%
1 week-0.73%
Current month-7.63%
1 month-3.28%
3 months-25.18%
6 months-13.26%
Current year-32.64%
1 week 77.35
Extreme 77.35
82.7
1 month 71.1
Extreme 71.1
87.3
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 4.51
Extreme 4.51
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
10/11/26 Exercice

Chief Executive Officer

17,728 0.0203%
9/29/26 Exercice

Director

-6,250 0.0072%
9/29/26 Exercice

Director

-4,863 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%-0.73%-3.11%+823.69% 7.85B
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
+0.09%-1.44%+23.40%-10.61% 24.23B
Average +0.03%+3.79%+46.91%+228.80% 40.04B
Weighted average by Cap. +0.11%+3.51%+48.28%+173.57%

Financials

2026 *2027 *
Net sales 4M 4.47M 3.69M 3.34M 6.25M 426M 6.35M 44.06M 17.58M 223M 16.77M 16.41M 705M 71.87M 80.24M 66.31M 60M 112M 7.64B 114M 791M 316M 4B 301M 295M 12.67B
Net income -317M -354M -293M -265M -496M -33.75B -504M -3.49B -1.39B -17.66B -1.33B -1.3B -55.94B -291M -325M -269M -243M -455M -30.97B -462M -3.21B -1.28B -16.21B -1.22B -1.19B -51.34B
Net Debt -1.02B -1.14B -938M -849M -1.59B -108B -1.61B -11.19B -4.47B -56.58B -4.26B -4.17B -179B -1.02B -1.13B -938M -848M -1.59B -108B -1.61B -11.19B -4.46B -56.55B -4.26B -4.17B -179B
Projected Income Statement - Annual - Abivax
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
98
Date Price Change Volume
26-10-29 €81.10 +0.43% 89,338
26-10-28 €80.75 +1.13% 72,420
26-10-27 €79.85 +2.37% 75,469
26-10-26 €78.00 -0.89% 53,381
26-10-23 €78.70 -3.67% 74,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Abivax
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
81.10EUR
Average target price
131.72EUR
Spread / Average Target
+62.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Abivax
  1. Stock Market
  2. Stocks
  3. ABVX Stock